Court Upholds Gilead's Trademark Rights in Drug Import Case

The Fourth Circuit Court of Appeals has upheld a lower court's decision to grant Gilead Sciences, Inc. a preliminary injunction against several companies involved in an alleged scheme to import prescription drugs into the United States without proper authorization. This ruling affects not only the companies involved but also has broader implications for drug pricing and healthcare practices in the U.S.

The case, Gilead Sciences, Inc. v. ProAct, Inc., was filed under docket number 25-1829. It centers on Gilead's claims that its trademarks were infringed when foreign-market versions of its HIV medication, Biktarvy, were imported and distributed in the U.S. The court's decision to affirm the injunction underscores the importance of trademark protections in the pharmaceutical industry.

Background

Gilead Sciences, Inc. is a biopharmaceutical company known for developing and marketing prescription medications, including Biktarvy, which is used to treat HIV. The issue arose when a Maryland patient received a Turkish version of Biktarvy through a series of transactions involving several companies, including ProAct, Meritain Health, and Rx Valet. These companies facilitated the importation of drugs intended for foreign markets, circumventing U.S. regulations.

The arrangement involved a self-funded health plan where an employer directly bears the financial risk of healthcare expenses. To cut costs, the employer contracted with alternative funding programs (AFPs) to import medications from abroad. Gilead discovered this scheme after the patient reported receiving a foreign version of its medication, prompting the company to investigate further.

In December 2024, Gilead filed a lawsuit against the Quartet—comprising Rx Valet, Advanced Pharmacy, Affordable RX, and Gregory Santulli—along with Meritain Health and ProAct. The lawsuit alleged trademark infringement and unfair competition under the Lanham Act, claiming that the imported medications were materially different from the U.S. version and thus violated Gilead's trademark rights.

The Ruling

The Fourth Circuit Court affirmed the district court's decision to grant Gilead a preliminary injunction. The court found that Gilead was likely to succeed on the merits of its claims, stating, "The district court concluded that Gilead is likely to succeed on the merits of its direct trademark infringement claims against the Quartet and its contributory trademark infringement claims against Meritain and ProAct." This ruling emphasizes the court's recognition of the potential for consumer confusion arising from the sale of foreign-market drugs in the U.S.

The judges involved in the ruling included Circuit Judges Agee and Harris, along with Senior Circuit Judge Keenan. The court's opinion highlighted that Gilead's trademarks were likely infringed because the foreign versions of Biktarvy were not authorized for sale in the U.S. and were materially different from the domestic version.

Impact

This ruling has significant implications for the pharmaceutical industry and self-funded health plans. It reinforces the importance of trademark protections in preventing unauthorized imports of medications, which can pose risks to patient safety and undermine the integrity of drug marketing. The decision may deter other companies from engaging in similar practices, potentially affecting the cost and availability of medications in the U.S.

Furthermore, the ruling highlights the legal complexities surrounding the importation of prescription drugs and the responsibilities of third-party administrators and pharmacy benefit managers in ensuring compliance with trademark laws. As self-funded health plans continue to seek cost-saving measures, the court's decision may influence how they approach drug sourcing and partnerships with AFPs.

What's Next

The Appellants have the option to appeal the ruling, but details on any potential further legal action were not available in the court filing. The outcome of this case could set a precedent for future trademark disputes in the pharmaceutical sector, particularly regarding the importation of foreign medications.